American Kidney Fund’s Post

🔬 Uncover the complexities of this unique case and its implications for treatment. Read the new published case report in our journal Medical Sciences MDPI titled "Double Hit of Hydroxichloroquine and Amiodarone Induced Renal Phospholipidosis in a Patient with Monoclonal Gammopathy and Sclerodermiform Syndrome: A Case Report and Review of the Literature". 👥 Authors: De la Flor, J. C. et al. 🔗 Read the article here: https://lnkd.in/dBG-XQJY #MedicalResearch #CaseReport #Hydroxychloroquine #Amiodarone

An “anti-hunger” molecule produced after vigorous exercise is responsible for the moderate weight loss caused by the diabetes medication metformin, according to a new study in mice and humans. The molecule, lac-phe, was discovered by Stanford Medicine researchers in 2022. The finding, made jointly by researchers at Stanford Medicine and at Harvard Medical School, further cements the critical role the molecule, called lac-phe, plays in metabolism, exercise and appetite. It may pave the way to a new class of weight loss drugs. “Until now, the way metformin, which is prescribed to control blood sugar levels, also brings about weight loss has been unclear,” said Jonathan Long, PhD, an assistant professor of pathology. “Now we know that it is acting through the same pathway as vigorous exercise to reduce hunger. Understanding how these pathways are controlled may lead to viable strategies to lower body mass and improve health in millions of people.” Long, who is supported by the Knight Initiative for Brain Resilience, and Mark Benson, MD, PhD, an assistant professor of medicine at Harvard Medical School, are co-senior authors of the study, which was published on March 18 in Nature Metabolism. Postdoctoral scholar Shuke Xiao, PhD, is the lead author of the study. Many people with diabetes who are prescribed metformin lose around 2% to 3% of their body weight within the first year of starting the drug. Although this amount of weight loss is modest when compared with the 15% or more often seen by people taking semaglutide drugs such as Ozempic and Wegovy, the discoveries that led to those drugs also grew from observations of relatively minor, but reproducible, weight loss in people taking first-generation versions of the medications. #👍👍

It was a pleasure to participate in this series focusing on evolution of non factor therapies.

Happy Clinical Trials Day! 🎉 In a recent study conducted at Stanford University , we delved into the comparison of the results between the outcomes of Mega-trials (involving over 10,000 participants) and smaller trials. 🔍 Smaller trials, conducted before Mega-trials, reported significantly larger positive results favoring the intervention—Primary Outcomes and All-Cause Mortality. 🌟🕛 This suggests that early pioneer studies often provided more optimistic, inflated results, which were later adjusted by the more extensive Mega-trials. 📊 Out of 120 Mega-trials we analyzed, only 39 (33%) showed significant results for Primary Outcomes and just 18 (15%) for All-Cause Mortality. These insights underscore the critical role of Mega-trials in refining our understanding and shaping clinical practice. Given their importance, we believe there is a need for more Mega-trials to ensure we obtain reliable and robust data for key medical interventions. Moreover, with the recent advancements, AI backed platforms can facilitate the conductance of such large trials. Here's to the incredible work being done in clinical trials to advance medical science and improve patient care! Taulant Muka, MD, MPH, PhD, PD Hamidreza Raeisi-Dehkordi Erand Llanaj, PhD Noushin Ahanchi Farnaz Khatami Renald Mecani Adea Llane #ClinicalTrialsDay #Research #Healthcare #MedicalScience #ClinicalResearch #Stanford

Familiarize yourself with the methods used to measure hormone concentrations and discover how to apply methods for assay standardization with Endocrine Society. https://lnkd.in/dSBuwaes

The study titled "Assessing the Burden and Knowledge, Attitudes, and Practices of Hepatitis B and Hepatitis C Among Dentists in Georgia" has been published in the Journal of Hepatology. I would like to extend my gratitude to the exceptional team of researchers for their high-quality work. A special thanks to Maia Tsereteli for giving me the opportunity to contribute to this important research. You can access the full publication here: DOI: https://lnkd.in/dcG3SeTC.

Congratulations to Prof Emmanuel Favaloro, our Principal Hospital Scientist NSW Health Pathology Westmead ICPMR, who has been recognised twice in the 2024 Research Magazine as a top researcher in the fields of haematology and clinical laboratory science. The Australian's 2024 Research magazine names the top researcher and top research institution in each of 250 fields of research, based on the number of citations for papers published in the top 20 journals in each field over the past five years. Link to article: https://ow.ly/7JnA50Rx2Hy Emmanuel’s expertise lies in bleeding and thrombosis disorder diagnosis and better patient care. Research has always played a large role throughout his remarkable career. His first research paper while based at Westmead was published in 1985. We asked him why investing in research is so important. "Good research contributes to our growing understanding of disease and by understanding disease, this enables us to provide better patient care and treatment," he said. His advice to others? "Always be curious and question what you think you know. That will develop new discoveries and innovation and improve the way we do things. But I also recognise that the more I know, the more I recognise that I don’t know, so there is always more to learn.” Watch his top 3 tips in the video below. Read more: https://lnkd.in/gtD_WdNQ #ForAllOfUs #NSWHP #Research #NSWHealthPathology

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) is seeking exceptional candidates for the position of Clinical Director to provide leadership in one of the preeminent Institutes. The NHLBI’s mission is to provide global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood disorders and enhance the health of all individual so that they can live longer and more fulfilling lives. The NHLBI Clinical Director is key to that mission within the Division of Intramural Research (DIR). The Clinical Director is a vital part of the Institute’s leadership team. The NHLBI DIR’s focus is to perform robust scientific and clinical research that leads to a better understanding of biology and clinical pathology. Building from a strong basic science foundation, the DIR’s clinical research program is multifaceted – from first-in-human clinical research trials to natural history studies of rare disease processes. This investigator-initiated work is supported by a robust clinical research infrastructure provided by the Office of the Clinical Director (OCD). #clinicaldirector #research #training #heart #lung #blooddisorders #clinicalresearch #biology #clinicalpathology #researchtrials

Did you know the first clinical trial was in the Bible? 🥕🍋 From Daniel’s diet experiment to James Lind’s scurvy breakthrough and William Withering’s heart drug discovery, these early trials paved the way for modern medicine. Learn how these simple tests laid the foundation for today’s life-saving treatments in our latest blog! 🧪✨ #MedicalHistory #ClinicalTrials #HealthcareInnovation #MedicalBreakthroughs https://lnkd.in/g_PdXbpc

Familiarize yourself with the methods used to measure hormone concentrations and discover how to apply methods for assay standardization with Endocrine Society. https://lnkd.in/gSwsdQpG